- American Medical Association. AMA PRA frequently asked questions for CME providers. 2016. https://www.ama-assn.org/sites/default/files/mediabrowser/public/cme/provider-faq-v2.pdf (accessed Oct 23, 2017).
- 2 Accreditation Council for Continuing Medical Education. Education ACCME. For physicians and healthcare professionals. 2017. http://www.accme.org/ physicians-and-health-care-professionals (accessed Oct 23, 2017).
- 3 Accreditation Council for Continuing Medical Education. Education ACCME. Joint providership. 2017. http://www.accme.org/physicians-and-health-care-professionals (accessed Oct 23, 2017).
- 4 Peck C, McCall M, McLaren B, Rotem T. Continuing medical education and continuing professional development: international comparisons. BMJ 2000; 320: 432–35.
- 5 Stevenson R, Pozniak E. Continuing medical education on the cusp of change. Advance Continuing Education Association. 2015. https:// aceaglobal.com/ce-industry/continuing-medical-education-on-the-cuspof-change/ (accessed Oct 23, 2017).
- 6 Paton J. Drugmakers' payments to UK health groups and doctors climb 25%. Bloomberg, June 30, 2017. https://www.bloomberg.com/news/ articles/2017-06-30/drugmakers-payments-to-u-k-health-groupsdoctors-climb-25 (accessed Oct 23, 2017).
- 7 Steinbrook R. Financial support of continuing medical education. IAMA 2008: 299: 1060–62.
- Relman AS. Industry support of medical education. JAMA 2008; 300: 1071–73.
- Steinbrook R. Commercial support and continuing medical education. N Engl J Med 2005; 352: 534-35.

- 10 Steinman MA, Landefeld CS, Baron RB. Industry support of CME—are we at the tipping point? N Engl J Med 2012; **366**: 1069–71.
- 11 Relman AS. Defending professional independence: ACCME's proposed new guidelines for commercial support of CME. JAMA 2003; **289**: 2418–20.
- 12 Steinbrook R. Future directions in industry funding of continuing medical education. Arch Intern Med 2011; 171: 257–58.
- 13 Peterson ED, Overstreet KM, Parochka JN, Lemon MR. Medical education and communication companies involved in CME: an updated profile. I Contin Educ Health Prof 2008: 28: 205–13.
- 14 Mack J. Waning pharma support of CME. Pharma Marketing News, August, 2009. http://www.news.pharma-mkting.com/pmn87-article03.pdf (accessed Oct 23, 2017).
- 15 Rothman S, Brudney K, Adair W, Rothman D. Medical communication companies and industry grant. JAMA 2013; 310: 2554-58.
- 16 Center for Medicare and Medicaid Services. Open payments. 2017. https://www.cms.gov/openpayments (accessed Oct 23, 2017).
- 17 Hawkes N. Indirect payments from drug companies to doctors for CME courses will be exempt from database. BMJ 2014; 349: g6676.
- 18 Silverman E. 21st Century Cures bill would weaken requirements for disclosing industry ties. Pharmalot, Nov 28, 2016. https://www.statnews. com/pharmalot/2016/11/28/21st-century-cures-sunshine (accessed Oct 23, 2017).
- 19 Cookson C. Database shines light on pharma payments to UK doctors. Financial Times, June 30, 2016. https://www.ft.com/content/b3e42806-3ec7-11e6-8716-a4a71e8140b0 (accessed Oct 23, 2017).





A global coalition for the fight against heart disease and stroke

Published Online October 16, 2017 http://dx.doi.org/10.1016/ S0140-6736(17)32676-4 As political leaders prepare for the third UN High-level Meeting on Non-communicable Diseases (NCDs) in 2018, the World Heart Federation (WHF) is bringing

Panel: Objectives of the Global Coalition for Circulatory Health

- Achieve the global target of a 25% reduction by 2025 in premature mortality from heart disease and stroke, as an essential component to the 25 by 25 NCD target and a key milestone to achieving the Sustainable Development Goal 3.4 of a one-third reduction in premature NCD deaths by 2030
- Unite the diverse voices of the circulatory health community to become more powerful advocates to policy makers and politicians
- Align all organisations to support the WHO Global Hearts Initiative⁶ to improve the prevention, control, and treatment of heart disease and stroke through primary health care
- Promote common international messaging by partnering organisations and leveraging their extensive networks to cascade messages to regional and national levels
- Strengthen the voice of people living with heart disease and stroke by including patients, their families, and communities in decision-making processes and in national, regional, and global advocacy
- Convene an annual Global Summit on Circulatory Health for professional leaders from the public and private sectors to drive the international, regional, and national agendas for circulatory health

together a global coalition of international, regional, and national stakeholders in cardiovascular diseases (CVDs) to drive the urgent action needed to combat heart disease and stroke.

CVDs are the leading cause of mortality worldwide, with more than 75% of these deaths occurring in low-income and middle-income countries.¹ Yet the huge burden of heart attacks and strokes is not being addressed with the priority required to achieve the 25% reduction in premature mortality from NCDs by 2025 (25 by 25),² an ambition only achievable through a substantial reduction in heart attacks and stroke. Nor are the implementation of the WHO Global Action Plan³ and national action plans on NCDs being driven by politicians and policy makers with sufficient vigour.

Given this slow progress, WHF convened the 1st Global Summit for Circulatory Health in June, 2016, that resulted in the Mexico Declaration.⁴ Adopted by 29 global, regional, and national civil society organisations, the signatories pledged to advocate for policies for cardiovascular health, develop a common implementation strategy based on evidence, and develop a common language for policy makers. Since then, we have seen the launch of Resolve,⁵ an initiative to prevent an additional 100 million deaths from CVDs globally, led by Tom Frieden, and the Global Hearts

Initiative,⁶ led by WHO in partnership with WHF, the World Stroke Organization, and the International Society of Hypertension, among others. The success of these initiatives will depend on political will and investment.

Inspiring a greater sense of urgency was the theme of WHF's 2nd Global Summit in Singapore in July, 2017, that was attended by the leaders of 88 organisations. In his opening address to the summit via video, Michael Bloomberg, the WHO Global Ambassador for NCDs, called for "bold action" to achieve 25 by 25. Richard Horton, the Editor-in-Chief of The Lancet, posed the guestion "Why are we failing to prevent the preventable given that we know the causes?", and Salim Yusuf challenged organisations to act now to translate scientific evidence into policy and action. The plenary and workshop discussions included topics on national CVD action plans, the WHO Global Hearts Initiative, WHF Roadmaps to 25 by 25,7 access to essential and affordable medicines and technologies, moving towards healthier cities, political advocacy, and building a civil society movement.

The need to coordinate international advocacy efforts became self-evident during discussions at the summit and a decision was made to form a global coalition of international, regional, and national stakeholders to work together for circulatory health. This Global Coalition for Circulatory Health is open to any professional organisation with a role in circulatory health. The coalition will leverage the expertise and reach of its international partners to advocate for increased prevention, control, and treatment of all circulatory diseases (panel).

As leaders in global health gather in Montevideo, Uruguay, on Oct 18–20, 2017, for the WHO Global Conference on Noncommunicable Diseases, we should remember that all organisations dedicated to tackling heart disease and stroke have their part to play. We can ensure our collective voice is heard more clearly by politicians and policy makers and, working together, accelerate the fight against heart disease and stroke.

*David Wood, Jean-Luc Eiselé

World Heart Federation, Geneva 1201, Switzerland (DW, J-LE); and Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK (DW) d.wood@imperial.ac.uk

DW is President and J-LE is Chief Executive Officer of the World Heart Federation. We declare no other competing interests.

- 1 WHO. Cardiovascular disease. 2017. http://www.who.int/cardiovascular_ diseases/en/ (accessed Sept 7, 2017).
- UN. Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. 2011. http://www.who.int/nmh/events/un_ncd_summit2011/political_ declaration_en.pdf?ua=1 (accessed Sept 7, 2017).
- 3 WHO. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020. 2013. http://apps.who.int/iris/ bitstream/10665/94384/1/9789241506236_ eng.pdf?ua=1 (accessed Sept 7, 2017).
- 4 World Heart Federation. Mexico Declaration. 2016. https://www.world-heart-federation.org/wp-content/uploads/2017/07/The-Mexico-Declaration-Circulatory-Health-for-All-People.pdf (accessed Sept 7, 2017).
- Vital Strategies. Vital Strategies launches Resolve. 2017. http://www.vitalstrategies.org/vital-stories/vital-strategies-launches-resolve-new-225-million-global-health-initiative/ (accessed Sept 7, 2017).
- 6 WHO. Global Hearts Initiative. 2016. http://www.who.int/cardiovascular_diseases/global-hearts/en/ (accessed Sept 7, 2017).
- 7 World Heart Federation. Global CVD Roadmaps. 2016. http://www.cvdroadmaps.org/ (accessed Sept 7, 2017).
- 8 WHO. WHO Global Conference on Noncommunicable Diseases: enhancing policy coherence between different spheres of policy making that have a bearing on attaining SDG target 3.4 on NCDs by 2030. 2017. http://www.who.int/nmh/events/2017/montevideo/about/en/ (accessed Sept 7, 2017).